Literature DB >> 26683137

Clostridium histolyticum collagenase - is this a revolutionary medical treatment for Peyronie's disease?

Chris Poullis1, Majid Shabbir2, Ian Eardley3, John Mulhall4, Suks Minhas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26683137      PMCID： PMC5568534          DOI： 10.1111/bju.13396

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  9 in total

1.  The preparation of purified collagenase.

Authors:  S KELLER; I MANDL
Journal:  Arch Biochem Biophys       Date:  1963-04       Impact factor: 4.013

2.  Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease.

Authors:  Martin Gelbard; Larry I Lipshultz; James Tursi; Ted Smith; Greg Kaufman; Laurence A Levine
Journal:  J Urol       Date:  2012-04-13       Impact factor: 7.450

3.  Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies.

Authors:  Larry I Lipshultz; Irwin Goldstein; Allen D Seftel; Gregory J Kaufman; Ted M Smith; James P Tursi; Arthur L Burnett
Journal:  BJU Int       Date:  2015-05-18       Impact factor: 5.588

Review 4.  EAU guidelines on penile curvature.

Authors:  Konstantinos Hatzimouratidis; Ian Eardley; François Giuliano; Dimitrios Hatzichristou; Ignacio Moncada; Andrea Salonia; Yoram Vardi; Eric Wespes
Journal:  Eur Urol       Date:  2012-05-25       Impact factor: 20.096

Review 5.  Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.

Authors:  Martin Gelbard; Irwin Goldstein; Wayne J G Hellstrom; Chris G McMahon; Ted Smith; James Tursi; Nigel Jones; Gregory J Kaufman; Culley C Carson
Journal:  J Urol       Date:  2013-01-31       Impact factor: 7.450

6.  The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.

Authors:  Gerald H Jordan
Journal:  J Sex Med       Date:  2008-01       Impact factor: 3.802

7.  Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study.

Authors:  M K Gelbard; K James; P Riach; F Dorey
Journal:  J Urol       Date:  1993-01       Impact factor: 7.450

8.  The use of collagenase in the treatment of Peyronie's disease.

Authors:  M K Gelbard; A Lindner; J J Kaufman
Journal:  J Urol       Date:  1985-08       Impact factor: 7.450

9.  Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

Authors:  Lawrence C Hurst; Marie A Badalamente; Vincent R Hentz; Robert N Hotchkiss; F Thomas D Kaplan; Roy A Meals; Theodore M Smith; John Rodzvilla
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245
  9 in total
  4 in total

1.  Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective.

Authors:  James Anaissie; Wayne J G Hellstrom; Faysal A Yafi
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 2.  Intralesional collagenase Clostridium histolyticum in the management of Peyronie's disease: current best practice.

Authors:  Daniel J Cwikla; Faysal A Yafi
Journal:  Ther Adv Urol       Date:  2018-02-08

Review 3.  Nonsurgical Interventions for Peyronie's Disease: Update as of 2016.

Authors:  Gregory A Joice; Arthur L Burnett
Journal:  World J Mens Health       Date:  2016-08-23       Impact factor: 5.400

Review 4.  Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives.

Authors:  Paige K Kuhlmann; Kenneth J DeLay; James Anaissie; Wayne Jg Hellstrom; Faysal A Yafi
Journal:  Patient Prefer Adherence       Date:  2017-03-02       Impact factor: 2.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.